Investment
Features
FeesSafety
Academy
More
Pluang+

Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs GSK plc (GSK) Price & Performance

VanEck JP Morgan EM Local Currency Bond ETFTrade

Price performance (Past 24H)

Key statistics

VanEck JP Morgan EM Local Currency Bond ETF vs GSK plc — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.6, while GSK plc trades at $51.15 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none, and GSK plc is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.

EMLCGSK
Sector
Fixed IncomeHealth
52-Week High
$26.59$61.18
52-Week Low
$24.83$38.22
Market Cap
$102.60B
Enterprise Value
$123.04B
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

VanEck JP Morgan EM Local Currency Bond ETF

EMLC trades at $25.615, showing minimal daily movement with a slight decline of 0.02%. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payments of $0.13-$0.14 per share. Emerging market debt exposure provides yield advantages over developed markets, though volatility remains a consideration.

The outlook for EMLC appears favorable given the Federal Reserve's accommodative stance and emerging market yield premiums. Key opportunities include attractive fixed income returns compared to Treasury bonds, while risks center on emerging market volatility and inflation concerns. The technical bullish signal supports near-term price stability with potential for gradual appreciation.

GSK plc

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About VanEck JP Morgan EM Local Currency Bond ETF

EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.

Read more on EMLC

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK